Skip to main content
Moberg Pharma logo

Moberg Pharma — Investor Relations & Filings

Ticker · MOB ISIN · SE0020353928 LEI · 549300XFXK7DVGDRP410 ST Manufacturing
Open in API
Filings indexed 785 across all filing types
Latest filing 2026-06-03 Major Shareholding Noti…
Country SE Sweden
Listing ST MOB

About Moberg Pharma

https://www.mobergpharma.com/

Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 95% confidence The document is a regulatory disclosure of a significant shareholding acquisition in Moberg Pharma AB, including detailed pre- and post-transaction share counts, voting rights percentages, and chain of controlling companies. It is published by the Swedish Financial Supervisory Authority (Finansinspektionen) under its major shareholding notification rules. This matches the Major Shareholding Notification category.
2026-06-03 English
Kommuniké från Moberg Pharmas årsstämma den 21 maj 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 88% confidence The document is a press release summarizing the decisions taken at the Annual General Meeting (AGM) on May 21, 2026: adoption of the financial statements, board and auditor elections, dividend decisions, remuneration guidelines, incentive program authorization, and amendments to the articles. It is not the full annual report nor the presentation slide deck; rather it reports the resolutions and outcomes of shareholder votes. This corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-21 Swedish
Bulletin from Moberg Pharma’s AGM on May 21[st], 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 87% confidence The document is a press release summarizing the resolutions and vote outcomes from the company’s Annual General Meeting – adoption of financial statements, election/re-election of board members and auditors, approval of remuneration, dividend decision, etc. This is a declaration of shareholder meeting voting results. Therefore it fits the Declaration of Voting Results category (DVA).
2026-05-21 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 90% confidence The document is clearly a comprehensive interim (quarterly) financial report for Moberg Pharma AB covering January–March 2026. It includes detailed financial metrics (net revenues, EBITDA, EBIT, EPS, cash position), management commentary, operational highlights during the quarter and after quarter end, and detailed narrative sections on product and market developments. This matches the definition of an Interim/Quarterly Report (IR) since it contains actual financial statements and substantive analysis for a period shorter than a full fiscal year. Q1 2026
2026-05-12 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 85% confidence The document is clearly titled “Interim report January – March 2026” and contains full quarter-by-quarter financial results (net revenue, EBITDA, operating profit, EPS, cash balances), CEO commentary, significant events during and after the quarter, clinical study updates, market approvals, and other substantive financial and operational details. It is a comprehensive interim/quarterly financial report, not merely an announcement or summary. Therefore, it corresponds to an Interim / Quarterly Report. Q1 2026
2026-05-12 English
Moberg Pharma och Karo Healthcare expanderar samarbete för MOB-015/Terclara till Australien, Nya Zeeland, Sydkorea och Taiwan
Regulatory Filings Classification · 60% confidence The document is a press release under MAR, announcing a new exclusive licensing agreement for commercialization of MOB-015/Terclara in new markets. It is not a financial report (Annual, Interim, or Earnings Release), not a dividend notice, not a management change, not a share transaction, not governance or ESG. It is a business update/further regulatory disclosure, falling into the general “Regulatory Filings” fallback category (RNS).
2026-04-24 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.